疑似肝素诱导的血小板减少症中替代抗凝治疗的成本-效果分析
基于瑞士最大医院2015至2018年住院数据构建决策树模型,评估阿加曲班、磺达肝癸钠和利伐沙班在疑似肝素诱导的血小板减少症(HIT)患者中的成本-效果。磺达肝癸钠和利伐沙班较阿加曲班避免更多不良事件,磺达肝癸钠成本更低并主导阿加曲班。
要点
- 避免1例不良事件总成本:阿加曲班49565瑞士法郎,磺达肝癸钠30380瑞士法郎,利伐沙班30610瑞士法郎。
- 经4Ts评分调整后:阿加曲班41152瑞士法郎,磺达肝癸钠27710瑞士法郎,利伐沙班37699瑞士法郎。
- 避免不良事件数:阿加曲班0.820,磺达肝癸钠0.834,利伐沙班0.917,磺达肝癸钠和利伐沙班临床更有效。
核心结论
- 磺达肝癸钠和利伐沙班较阿加曲班避免更多不良事件,但磺达肝癸钠成本节约更大。
- 磺达肝癸钠可能成为阿加曲班的可行替代方案。
研究设计与样本
- 基于瑞士最大医院2015至2018年住院数据构建决策树模型,评估疑似HIT患者使用获批及超说明书抗凝药的成本-效果。
- 成本数据来自财务部门或根据瑞士全国成本费率估算,主要结局为避免的不良事件和增量成本-效果比。
- 进行确定性和概率敏感性分析,共2000次模拟以评估结果稳健性。
主要发现
- 基础病例分析中,避免1例不良事件总成本:阿加曲班组49565瑞士法郎,磺达肝癸钠组30380瑞士法郎,利伐沙班组30610瑞士法郎。
- 经4Ts评分调整后,避免1例不良事件总成本:阿加曲班组41152瑞士法郎,磺达肝癸钠组27710瑞士法郎,利伐沙班组37699瑞士法郎。
- 避免的不良事件数:阿加曲班组0.820,磺达肝癸钠组0.834,利伐沙班组0.917。
- 磺达肝癸钠治疗成本更低且避免更多不良事件,因此主导阿加曲班。
- 结果对不良事件发生率和住院延长最为敏感,蒙特卡洛模拟证实了基础病例分析结果。
关键数值与推荐
- 避免1例不良事件总成本:阿加曲班49565瑞士法郎,磺达肝癸钠30380瑞士法郎,利伐沙班30610瑞士法郎。
- 经4Ts评分调整后避免1例不良事件总成本:阿加曲班41152瑞士法郎,磺达肝癸钠27710瑞士法郎,利伐沙班37699瑞士法郎。
- 避免的不良事件数:阿加曲班0.820,磺达肝癸钠0.834,利伐沙班0.917。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heparin-induced thrombocytopenia (HIT) is a life-threatening complication associated with high medical costs. Factor Xa inhibitors gradually replace approved treatment with intravenous direct thrombin inhibitors despite their off-label indication, because of easier management and favorable economic profile. Whether they are cost-effective remains unclear. We evaluated the cost-effectiveness of approved and off-label anticoagulants in patients with suspected HIT, based on census data from the largest Swiss hospital between 2015 and 2018. We constructed a decision tree model that reflects important clinical events associated with HIT. Relevant cost data were obtained from the finance department or estimated based on the Swiss-wide cost tariff. We estimated averted adverse events (AEs) and incremental cost-effectiveness ratio as primary outcome parameters. We performed deterministic and probabilistic sensitivity analyses with 2000 simulations to assess the robustness of our results. In the base-case analysis, the total cost of averting 1 AE was 49 565 Swiss francs (CHF) for argatroban, 30 380 CHF for fondaparinux, and 30 610 CHF for rivaroxaban; after adjusting for 4Ts score: 41 152 CHF (argatroban), 27 710 CHF (fondaparinux), and 37 699 CHF (rivaroxaban). Fondaparinux and rivaroxaban were more clinically effective than argatroban, with AEs averted of 0.820, 0.834, and 0.917 for argatroban, fondaparinux, and rivaroxaban, respectively. Treatment with fondaparinux resulted in less cost and more AEs averted, hence dominating argatroban. Results were most sensitive to AE rates and prolongation of stay. Monte Carlo simulations affirmed our base-case analysis. This is the first cost-effectiveness analysis comparing argatroban with fondaparinux and rivaroxaban using primary data. Fondaparinux and rivaroxaban resulted in more averted AEs, but fondaparinux had greater cost savings. Fondaparinux could be a viable alternative to argatroban.
引用
- Tuleja A, Salvador D, Muka T, et al. Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia. Blood Adv. 2022. PMID: 35147675. doi:10.1182/bloodadvances.2022007017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。